AstraZeneca Explores Development of mRNA Cancer Vaccines
AstraZeneca (AZN) is considering an entry into the cancer vaccine market, following recent clinical developments by competitors. The move comes after Moderna (MRNA) and Merck (MRK) demonstrated potential with their personalized neoantigen therapy, intismeran autogene. The pharmaceutical giant's research and development team has reportedly been conducting extensive work in this area to evaluate the viability of messenger-RNA-based technologies for oncology. This strategic pivot aims to capitalize on the growing interest in individualized immunotherapy treatments.
Topics: cancer vaccines mRNA technology oncology